Johnson & Johnson (JNJ) reported Q3 EPS of $2.55, $0.03 better than the analyst estimate of $2.52. Revenue for the quarter came in at $23.79 billion versus the consensus estimate of $23.46 billion.
GUIDANCE:
Company is maintaining 2022 full-year guidance midpoints for adjusted operational sales and reported adjusted EPS; increasing adjusted operational EPS performance offsetting continued unfavorable currency impact